Soleno Therapeutics, Inc. (SLNO): Price and Financial Metrics
GET POWR RATINGS... FREE!
SLNO Stock Price Chart Interactive Chart >
SLNO Price/Volume Stats
| Current price | $0.17 | 52-week high | $1.67 |
| Prev. close | $0.17 | 52-week low | $0.13 |
| Day low | $0.16 | Volume | 747,100 |
| Day high | $0.18 | Avg. volume | 598,586 |
| 50-day MA | $0.21 | Dividend yield | N/A |
| 200-day MA | $0.52 | Market Cap | 13.49M |
Soleno Therapeutics, Inc. (SLNO) Company Bio
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The companys lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
Latest SLNO News From Around the Web
Below are the latest news stories about Soleno Therapeutics Inc that investors may wish to consider to help them evaluate SLNO as an investment opportunity.
Soleno Therapeutics to Participate in the BIO CEO & Investor ConferenceREDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:15 PM Eastern Time. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercializati |
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to new employees. The independent members of the Board of Directors of Soleno approved the grant of a non-qualified stock option to purchase 70,000 shares of common stock to each of Scott Madsen |
Soleno Concludes Type C Meeting With FDA For Diazoxide Choline In Prader-Willi SyndromeSoleno Therapeutics Inc (NASDAQ: SLNO ) said that on January 20, 2022, the Company received official meeting minutes from the Type C meeting with the FDA''s Division of Psychiatry. The purpose of the meeting was to discuss the adequacy of the data submitted by Soleno to the FDA and possible ways to generate additional Full story available on Benzinga.com |
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi SyndromeREDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS). On January 20, 2022, the |
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access EventREDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event. Details for the panel discussions are below: Title:Patient Advocacy: Honing the Skill for Crossover Communicat |
SLNO Price Returns
| 1-mo | -14.96% |
| 3-mo | -47.42% |
| 6-mo | -73.95% |
| 1-year | -83.50% |
| 3-year | -93.90% |
| 5-year | -94.85% |
| YTD | -58.54% |
| 2021 | -78.76% |
| 2020 | -34.35% |
| 2019 | 71.93% |
| 2018 | -5.00% |
| 2017 | -55.56% |
Loading social stream, please wait...